The central role of the alternative complement pathway in human disease

被引:332
作者
Thurman, JM
Holers, VM
机构
[1] Univ Colorado, Hlth Sci Ctr, Div Rheumatol, Dept Med, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Div Nephrol & Hypertens, Denver, CO 80262 USA
[3] Univ Colorado, Hlth Sci Ctr, Div Rheumatol, Dept Immunol, Denver, CO 80262 USA
关键词
D O I
10.4049/jimmunol.176.3.1305
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The complement system is increasingly recognized as important in the pathogenesis of tissue injury in vivo following immune, ischemic, or infectious insults. Within the complement system, three pathways are capable of initiating the processes that result in C3 activation: classical alternative, and lectin. Although the roles that proinflammatory peptides and complexes generated during complement activation play in mediating disease processes have been studied extensively, the relative contributions of the three activating pathways is less well understood. Herein we examine recent evidence that the alternative complement pathway plays a key and, in most instances, obligate role in generating proinflammatory complement activation Products in vivo. In addition, we discuss new concepts regarding the mechanisms by which the alternative pathway is activated in vivo, as recent clinical findings and experimental results have provided evidence that continuous active control of this pathway is necessary to prevent unintended targeting and injury to self tissues. The Journal of Immunology, 2006.
引用
收藏
页码:1305 / 1310
页数:6
相关论文
共 82 条
[1]   Membranoproliferative glomerulonephritis type II (dense deposit disease):: An update [J].
Appel, GB ;
Cook, HT ;
Hageman, G ;
Jennette, JC ;
Kashgarian, M ;
Kirschfink, M ;
Lambris, JD ;
Lanning, L ;
Lutz, HU ;
Meri, S ;
Rose, NR ;
Salant, DJ ;
Sethi, S ;
Smith, RJH ;
Smoyer, W ;
Tully, HF ;
Tully, SP ;
Walker, P ;
Welsh, M ;
Würzner, R ;
Zipfel, PF .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (05) :1392-1403
[2]   Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice [J].
Bao, LH ;
Haas, M ;
Kraus, DM ;
Hack, BK ;
Rakstang, JK ;
Holers, VM ;
Quigg, RJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (03) :670-679
[3]   Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice [J].
Bao, LH ;
Haas, M ;
Boackle, SA ;
Kraus, DM ;
Cunningham, PN ;
Park, P ;
Alexander, JJ ;
Anderson, RK ;
Culhane, K ;
Holers, VM ;
Quigg, RJ .
JOURNAL OF IMMUNOLOGY, 2002, 168 (07) :3601-3607
[4]  
Blackmore TK, 1998, J IMMUNOL, V160, P3342
[5]   COMPLEMENT RECEPTORS AND PHAGOCYTOSIS [J].
BROWN, EJ .
CURRENT OPINION IN IMMUNOLOGY, 1991, 3 (01) :76-82
[6]   Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease [J].
Caprioli, J ;
Castelletti, F ;
Bucchioni, S ;
Bettinaglio, P ;
Bresin, E ;
Pianetti, G ;
Gamba, S ;
Brioschi, S ;
Daina, E ;
Remuzzi, G ;
Noris, M .
HUMAN MOLECULAR GENETICS, 2003, 12 (24) :3385-3395
[7]  
Carroll M C, 2000, Adv Immunol, V74, P61
[8]   Complement activation following reoxygenation of hypoxic human endothelial cells:: Role of intracellular reactive oxygen species, NF-κB and new protein synthesis [J].
Collard, CD ;
Agah, A ;
Stahl, GL .
IMMUNOPHARMACOLOGY, 1998, 39 (01) :39-50
[9]   Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome [J].
Dragon-Durey, MA ;
Loirat, C ;
Cloarec, S ;
Macher, MA ;
Blouin, J ;
Nivet, H ;
Weiss, L ;
Fridman, WH ;
Frémeaux-Bacchi, V .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (02) :555-563
[10]   Complement factor H polymorphism and age-related macular degeneration [J].
Edwards, AO ;
Ritter, R ;
Abel, KJ ;
Manning, A ;
Panhuysen, C ;
Farrer, LA .
SCIENCE, 2005, 308 (5720) :421-424